FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2759664130> ?p ?o ?g. }

• W2759664130 endingPage "4051" @default.
• W2759664130 startingPage "4042" @default.
• W2759664130 abstract "Cancer cells have altered metabolism and, in some cases, an increased demand for cholesterol. It is important to identify novel, rational treatments based on biology, and cellular cholesterol metabolism as a potential target for cancer is an innovative approach. Toward this end, we focused on diffuse large B-cell lymphoma (DLBCL) as a model because there is differential cholesterol biosynthesis driven by B-cell receptor (BCR) signaling in germinal center (GC) versus activated B-cell (ABC) DLBCL. To specifically target cellular cholesterol homeostasis, we employed high-density lipoprotein-like nanoparticles (HDL NP) that can generally reduce cellular cholesterol by targeting and blocking cholesterol uptake through the high-affinity HDL receptor, scavenger receptor type B-1 (SCARB1). As we previously reported, GC DLBCL are exquisitely sensitive to HDL NP as monotherapy, while ABC DLBCL are less sensitive. Herein, we report that enhanced BCR signaling and resultant de novo cholesterol synthesis in ABC DLBCL drastically reduces the ability of HDL NPs to reduce cellular cholesterol and induce cell death. Therefore, we combined HDL NP with the BCR signaling inhibitor ibrutinib and the SYK inhibitor R406. By targeting both cellular cholesterol uptake and BCR-associated de novo cholesterol synthesis, we achieved cellular cholesterol reduction and induced apoptosis in otherwise resistant ABC DLBCL cell lines. These results in lymphoma demonstrate that reduction of cellular cholesterol is a powerful mechanism to induce apoptosis. Cells rich in cholesterol require HDL NP therapy to reduce uptake and molecularly targeted agents that inhibit upstream pathways that stimulate de novo cholesterol synthesis, thus, providing a new paradigm for rationally targeting cholesterol metabolism as therapy for cancer." @default.
• W2759664130 created "2017-10-06" @default.
• W2759664130 creator A5006290111 @default.
• W2759664130 creator A5009157428 @default.
• W2759664130 creator A5010130956 @default.
• W2759664130 creator A5010703102 @default.
• W2759664130 creator A5043326132 @default.
• W2759664130 creator A5043989944 @default.
• W2759664130 creator A5073890024 @default.
• W2759664130 creator A5079703669 @default.
• W2759664130 creator A5083642951 @default.
• W2759664130 creator A5087559347 @default.
• W2759664130 date "2017-10-03" @default.
• W2759664130 modified "2023-10-14" @default.
• W2759664130 title "Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin" @default.
• W2759664130 cites W1020989877 @default.
• W2759664130 cites W1862079335 @default.
• W2759664130 cites W188859514 @default.
• W2759664130 cites W1919595924 @default.
• W2759664130 cites W1935694167 @default.
• W2759664130 cites W1970400561 @default.
• W2759664130 cites W1985170971 @default.
• W2759664130 cites W1987000997 @default.
• W2759664130 cites W1990394752 @default.
• W2759664130 cites W1993592678 @default.
• W2759664130 cites W2001399280 @default.
• W2759664130 cites W2002862770 @default.
• W2759664130 cites W2005082260 @default.
• W2759664130 cites W2015894544 @default.
• W2759664130 cites W2028858008 @default.
• W2759664130 cites W2032860037 @default.
• W2759664130 cites W2043398720 @default.
• W2759664130 cites W2051434186 @default.
• W2759664130 cites W2053747871 @default.
• W2759664130 cites W2055457307 @default.
• W2759664130 cites W2061621597 @default.
• W2759664130 cites W2067257663 @default.
• W2759664130 cites W2071059385 @default.
• W2759664130 cites W2083753651 @default.
• W2759664130 cites W2094102413 @default.
• W2759664130 cites W2101186431 @default.
• W2759664130 cites W2101375502 @default.
• W2759664130 cites W2108608979 @default.
• W2759664130 cites W2141892812 @default.
• W2759664130 cites W2147246240 @default.
• W2759664130 cites W2148733940 @default.
• W2759664130 cites W2152602965 @default.
• W2759664130 cites W2164637490 @default.
• W2759664130 cites W2252857421 @default.
• W2759664130 cites W2318212267 @default.
• W2759664130 cites W2323623316 @default.
• W2759664130 cites W2329322616 @default.
• W2759664130 cites W2344747184 @default.
• W2759664130 cites W2399367310 @default.
• W2759664130 cites W2408130038 @default.
• W2759664130 cites W2461193038 @default.
• W2759664130 cites W2509291718 @default.
• W2759664130 cites W2529817530 @default.
• W2759664130 cites W2554863679 @default.
• W2759664130 cites W2566957402 @default.
• W2759664130 cites W2571465655 @default.
• W2759664130 cites W2600125998 @default.
• W2759664130 doi "https://doi.org/10.1021/acs.molpharmaceut.7b00710" @default.
• W2759664130 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6004607" @default.
• W2759664130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28933554" @default.
• W2759664130 hasPublicationYear "2017" @default.
• W2759664130 type Work @default.
• W2759664130 sameAs 2759664130 @default.
• W2759664130 citedByCount "30" @default.
• W2759664130 countsByYear W27596641302018 @default.
• W2759664130 countsByYear W27596641302019 @default.
• W2759664130 countsByYear W27596641302020 @default.
• W2759664130 countsByYear W27596641302021 @default.
• W2759664130 countsByYear W27596641302022 @default.
• W2759664130 countsByYear W27596641302023 @default.
• W2759664130 crossrefType "journal-article" @default.
• W2759664130 hasAuthorship W2759664130A5006290111 @default.
• W2759664130 hasAuthorship W2759664130A5009157428 @default.
• W2759664130 hasAuthorship W2759664130A5010130956 @default.
• W2759664130 hasAuthorship W2759664130A5010703102 @default.
• W2759664130 hasAuthorship W2759664130A5043326132 @default.
• W2759664130 hasAuthorship W2759664130A5043989944 @default.
• W2759664130 hasAuthorship W2759664130A5073890024 @default.
• W2759664130 hasAuthorship W2759664130A5079703669 @default.
• W2759664130 hasAuthorship W2759664130A5083642951 @default.
• W2759664130 hasAuthorship W2759664130A5087559347 @default.
• W2759664130 hasBestOaLocation W27596641302 @default.
• W2759664130 hasConcept C185592680 @default.
• W2759664130 hasConcept C203014093 @default.
• W2759664130 hasConcept C2778163477 @default.
• W2759664130 hasConcept C2778559949 @default.
• W2759664130 hasConcept C2779338263 @default.
• W2759664130 hasConcept C2780072125 @default.
• W2759664130 hasConcept C41443022 @default.
• W2759664130 hasConcept C43554185 @default.
• W2759664130 hasConcept C502942594 @default.
• W2759664130 hasConcept C55493867 @default.
• W2759664130 hasConcept C86803240 @default.

• next